Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Medical Monitor Continuously Scans Intravenous Therapy

By HospiMedica International staff writers
Posted on 20 Apr 2016
A novel intravenous (IV) therapy monitor improves patient safety through early detection of peripheral venous infiltration (PVI) and extravasation.

The ivWatch model 400 is a noninvasive sensor that uses a near-infrared (NIR) optical sensor to illuminate the tissue near the IV insertion site. More...
The sensor is placed in a disposable receptacle and fixed next to the IV site, so that it can continuously monitor the tissue’s optical properties. The optical sensor is coupled to a highly intuitive, pole-mounted monitor equipped with a color liquid-crystal display (LCD) screen to continuously display patient IV status.

The optical sensor both emits NIR light and detects it returning from the skin. The optical data is then processed using a proprietary diagnostic algorithm to determine patient status. Status and status changes are displayed on-screen, along with an audible notification, alerting staff when conditions suggest that a PVI or extravasation has occurred, thus reducing patient harms. The ivWatch 400 is a product of ivWatch (Williamsburg, VA, USA), and has been approved by the US Food and Drug Administration (FDA).

“It’s like a seatbelt; since it’s difficult to predict when an accident will occur, people wear their seatbelt for the duration of their travel,” said Gary Warren, President and CEO of ivWatch. “Similarly, since it’s difficult to predict when an infiltration will occur, and we know it occurs too frequently, the ivWatch Model 400 represents a seat belt for patients with an IV. Our continuous monitoring device not only improves patient safety, but can help minimize the risk and avoidable costs for health care provider organizations.”

Complications of PVI are usually restricted to pain and redness, but in severe cases may result in tissue necrosis, loss of function, amputation or even death. To avoid potential failure, clinicians have defaulted to using often more intrusive vascular access devices, such as peripherally inserted central catheters (PICC). Unfortunately, these devices can carry other serious risks, such as central-line-associated bloodstream infection (CLABSI).

Related Links:

ivWatch    




Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Isolation Stretcher
IS 736
Gynecological Examination Chair
arco-matic
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.